Startup Qwyk enables Logistics providers to create their own Online Shipping Schedules
ROTTERDAM, The Netherlands, May 08, 2018 (GLOBE NEWSWIRE) -- Logistics tech startup Qwyk announced the public launch of their QwykSchedules(TM) product. Qwyk's products are designed to transform the way logistics companies interact with their customers.
QwykSchedules is a new product that aims to offer a digital solution for logistics companies who want to publish and market their services online. With QwykSchedules, subscribing companies can construct their own departure schedules by setting up routing rules. They can either host it in the cloud through a fully customizable page on the Qwyk platform or integrate it into their site and TMS through APIs (Application Programming Interfaces or Web services.) Promising extremely low maintenance, Qwyk's engine uses the routing rules to compile subscriber's schedules once a customer searches and provides real-time data based on what their assigned providers offer.
"Having been involved in the logistics industry for over 10 years, both on the Business side and Technology side, I have seen first-hand the challenges companies face. One challenge specifically is in getting the often tens of thousands of services offered to be visible in a searchable way," says Founder Martyn Verhaegen. "With the advent of the Digital Freight Forwarder, who have marketed themselves as an alternative on the premise that they can provide the visibility BCO's and other parties are looking for, that their 'traditional' counterparts cannot. It is becoming increasingly important for logistics companies to fill these visibility gaps."
"Together with rates and tracking data, we believe, services guide and schedule information form the cornerstones of supply chain visibility," the Netherlands based innovator adds. "With QwykSchedules, we aim to offer logistics industry parties a low-maintenance, affordable, and reliable way to get their services and schedules online and searchable by their customers within hours."
The online product, which has been in use by a number of subscribers, provides an easy-to-use interface in which subscribers can pick the Air, Ocean FCL and LCL providers they need and link them to a powerful routing guide which constructs end-to-end and multimodal trade lanes. Shippers and other parties can then use the subscriber's dedicated front-end page to conveniently search through their schedules.
"The potential for QwykSchedules lies in the fact that this is a product that provides an output immediately consumable by subscriber's customers. Traditional sailing schedule feeds generally leave it to their customers to transform the data they provide into something that is relevant and presentable while ingesting a lot of waste-data in the process. Along with the feeds, we also provide the software to do that transformation and immediately serve solutions to customers," Martyn Verhaegen explains.
"Our objective is to have new subscribers set up with their schedules in hours, not days or weeks, handling use-cases from simple port-to-port services to complex multi-leg point-to-point moves, including configurable pre- and on-carriage schedules, across all modalities. End-to-end services are the industry's end-game and the solution can scale to fit companies of any size, from local forwarders and NVO's to global enterprises."
Qwyk launched in early 2017 and was founded on the belief in automating and re-using existing data through intelligent transformations, to achieve related objectives and visibility and minimize costly human maintenance efforts. Qwyk's products are able to be tailored to your branding and marketing requirements at moment's notice. Meaning, although your customers may be using Qwyk's technology, to them it will still feel like it is entirely yours.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Qwyk - B.V. via Globenewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Følg saker fra GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra GlobeNewswire
WillScot to Participate at the Barclays Industrial Select Conference16.1.2019 21:00 | Pressemelding
BALTIMORE, Jan. 16, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”)(NASDAQ: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Barclays Industrial Select Conference at the Loews Miami Beach Hotel in Miami, Florida, on Wednesday, Feb. 20, 2019. The presentation will take place at 10:20 a.m. EST. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the WillScot family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol “WSC.” WillScot is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. It is the modular space supplier of choice for t
CCI has been retained by Waterloo Brewing to obtain Cannabis Licence16.1.2019 16:00 | Pressemelding
TORONTO, Jan. 16, 2019 (GLOBE NEWSWIRE) -- Cannabis Compliance Inc., (CCI) of Toronto, Ontario is pleased to announce they have partnered with Waterloo Brewing to help them obtain their Research and standard Processing Licence to develop cannabis-infused beverages. “CCI is working with Waterloo Brewing on the early stages of the application process and we are confident that we will help them achieve their desired licenses in time to be an active player in this growing sector of the cannabis industry”, said Brian Wagner, CEO and Founder, Cannabis Compliance Inc. “We are here to guide our clients through the early stages of the licensing process and for the many Health Canada requirements thereafter.” CCI offers end to end business solutions for cannabis companies large and small. Our team brings with them years of experience in the quality, regulatory, security and cultivation sectors, and supports manufacturers and retailers through regulatory challenges. As the world’s largest and mos
Aryaka Announces Expansion of Senior Leadership Team with New Chief Revenue Officer, Chief Transformation Officer and Chief Marketing Officer16.1.2019 15:00 | Pressemelding
Karen Freitag, Michelle Owczarzak, & Shashi Kiran join Aryaka to address significant growth and assist global enterprises in adopting managed connectivity as-a-service SAN MATEO, Calif., Jan. 16, 2019 (GLOBE NEWSWIRE) -- Aryaka®, announced today the appointment of several new executive hires to the company’s leadership team, including Karen Freitag (Chief Revenue Officer), Michelle Owczarzak (Chief Transformation Officer), and Shashi Kiran (Chief Marketing Officer). “Connectivity is the lifeblood of the global enterprise and Aryaka is the industry benchmark for secure managed connectivity worldwide. We are excited to have experienced industry veterans join our robust executive leadership team and continue to help build upon the immense success and growth that Aryaka has seen in recent years,” said Matt Carter, CEO of Aryaka. “As our customers expand globally, embrace SD-WAN, or move to the cloud, we’re becoming the de facto choice for their needs to make this happen better, faster, che
ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-601 in Advanced Solid Tumors16.1.2019 07:00 | Pressemelding
Pyrrolobenzodiazepine-based antibody drug conjugate targets AXL, a receptor tyrosine kinase highly expressed in solid tumors LAUSANNE, Switzerland, Jan. 16, 2019 (GLOBE NEWSWIRE) -- ADC Therapeutics, an oncology drug discovery and development company that specializes in the development of proprietary antibody drug conjugates (ADCs), today announced that the first patient has been dosed in its Phase I clinical trial evaluating the safety, tolerability, pharmacokinetics and anti-tumor activity of ADCT-601 in patients with selected solid tumors that are locally advanced or metastatic. ADCT-601 is an ADC composed of a humanized monoclonal antibody against human AXL, conjugated using GlycoConnect™ site specific conjugation technology to a pyrrolobenzodiazepine (PBD) dimer toxin. In preclinical studies, ADCT-601 demonstrated potent and specific in vitro and in vivo anti-tumor activity in multiple cancer-derived models with different levels of AXL expression, and was stable and well tolerated
GSA Europe’s Managing Director Elected Co-lead of CEN’s TC456 Committee15.1.2019 21:12 | Pressemelding
SAN GWANN, Malta, Jan. 15, 2019 (GLOBE NEWSWIRE) -- GSA Europe’s Managing Director Mark Pace has been elected by the Comité Européen de Normalisation (CEN) to lead the creation of a European Union online gaming reporting standard. CEN has established Technical Committee 456 to create this standard in support of online gambling supervision. GSA Europe joined Technical Committee 456 as a Liaison Organization in 2017. The Technical Committee’s mandate from the European Commission is directly aligned with work that GSA Europe has already started, namely, to create a single standard set of data elements and single standard way in which data is provided by online gambling providers to EU Member State regulatory authorities. In addition to joining and now leading the Technical Committee’s work, GSA Europe also donated their draft Regulatory Data Set and Regulatory Reporting Interface to CEN seeking to help jump-start the Committee’s work. “Joining CEN’s TC456 as a Liaison Organization, and no
Orion Biotechnology Reports Positive Results for Colorectal Cancer in Preclinical Study15.1.2019 15:00 | Pressemelding
OTTAWA, Jan. 15, 2019 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced preclinical data produced in collaboration with Charles River Laboratories, evaluating the efficacy of OB-002O (5P12-RANTES) in colorectal cancer. BALB/c mice were inoculated subcutaneously with the CT-26 colorectal cancer cell line. Three days after inoculation intraperitoneal treatment was started with OB-002O, a murine anti-PD-1 antibody, OB-002 + anti-PD-1, or saline placebo. Treatment was given daily or every third day. Treatment with OB-0020 alone led to statistically significant delayed tumor growth at multiple time-points. An even more profound effect on the decrease in mean tumor volume was observed in combination cohort where animals received both, OB-0020 and the anti-PD-1 antibody (p>0.05). “There is growing awareness of the role of CCR5 antagonism as an important component of cancer immunotherapy. OB-002O is an extremely potent CCR5 antagonist